Aaron Rosenberg

Treasurer, Director & Senior Vice President at Acceleron Pharma, Inc.

Aaron Rosenberg

Aaron Rosenberg

Treasurer, Director & Senior Vice President at Acceleron Pharma, Inc.

Biography

Presently, Aaron Rosenberg occupies the position of Treasurer, Director & Senior Vice President at Acceleron Pharma, Inc.

Overview
Number of Boards

1

Paths to Aaron Rosenberg
Potential Connections via
Relationship Science
You
Aaron Rosenberg
Treasurer, Director & Senior Vice President at Acceleron Pharma, Inc.
Career History
Treasurer, Director & Senior Vice President
2021 - Current

At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer. Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.

Boards & Committees
Treasurer, Director & Senior Vice President
2021 - Current

At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-ß) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of biologic therapies targeted to key mechanisms underlying blood diseases and cancer. Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.

Other Affiliations

Aaron Rosenberg is affiliated with Acceleron Pharma, Inc., Acceleron Pharma, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Aaron Rosenberg. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Aaron Rosenberg's profile does not indicate a business or promotional relationship of any kind between RelSci and Aaron Rosenberg.